Get the Stockscreener App
13.66
4.41%
-0.63
After Hours:
13.62
-0.04
-0.29%
Neuropace Inc stock is traded at $13.66, with a volume of 366.33K.
It is down -4.41% in the last 24 hours and up +14.50% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
See More
Previous Close:
$14.29
Open:
$14.36
24h Volume:
366.33K
Relative Volume:
3.24
Market Cap:
$407.73M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-10.76
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
-3.74%
1M Performance:
+14.50%
6M Performance:
+89.72%
1Y Performance:
-12.99%
1-Day Range:
$13.53
$14.40
1-Week Range:
$13.21
$14.40
52-Week Range:
$5.45
$18.15
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.66 | 407.73M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
Cantor Fitzgerald Forecasts Lower Earnings for NeuroPace - MarketBeat
Morgan Stanley Reduces Stake in NeuroPace Inc: A Strategic Portf - GuruFocus.com
JPMorgan Chase & Co. Has $84,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Wells Fargo & Company Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace, Inc. to Present Findings on RNS System for Focal Epilepsy at AAN 2025 Annual Meeting - Nasdaq
NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th9th - The Manila Times
Major Epilepsy Treatment Breakthrough: NeuroPace's RNS System Data Coming to AAN 2025 - StockTitan
Leerink Partnrs Estimates NeuroPace FY2029 Earnings - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 3,200 Shares - MarketBeat
NeuroPace FY2025 EPS Forecast Reduced by Cantor Fitzgerald - Defense World
Wells Fargo & Company Boosts NeuroPace (NASDAQ:NPCE) Price Target to $17.00 - Defense World
Leerink Partnrs Predicts NeuroPace FY2029 Earnings - Defense World
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com India
NeuroPace’s SWOT analysis: epilepsy device maker’s stock poised for growth By Investing.com - Investing.com Nigeria
Neuropace chief medical officer Morrell sells $48,032 in stock - MSN
NeuroPace Expects 2025 Revenue Growth -January 29, 2025 at 03:36 am EST - Marketscreener.com
Neuropace chief medical officer Morrell sells $48,032 in stock By Investing.com - Investing.com Australia
NeuroPace Projects 2025 Growth and Product Enhancements - TipRanks
NeuroPace Issues 2025 Financial Guidance Targets - The Manila Times
NeuroPace Issues 2025 Financial Guidance Targets -January 28, 2025 at 05:16 pm EST - Marketscreener.com
NeuroPace's Bold Plan to Transform Epilepsy Treatment: AI, New Markets, and 20% Growth - StockTitan
How the (NPCE) price action is used to our Advantage - Stock Traders Daily
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump - Simply Wall St
Cantor Fitzgerald Comments on NeuroPace FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts NeuroPace FY2025 Earnings - MarketBeat
UBS Group Begins Coverage on NeuroPace (NASDAQ:NPCE) - Defense World
Barclays PLC Buys 16,007 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock? - Yahoo Finance
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - Investing.com Australia
NeuroPace (NASDAQ:NPCE) Now Covered by Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - Nasdaq
Kck Ltd. Purchases Shares of 5,270,845 NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Receives $15.00 Average Target Price from Brokerages - Defense World
NeuroPace to Present at J.P. Morgan Healthcare Conference - TipRanks
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth By Investing.com - Investing.com Australia
NeuroPace reports preliminary Q4 revenue - MSN
NeuroPace Inc (NPCE): A New Perspective - Stocks Register
NeuroPace Shares Updates on Financial Performance and Board of Directors - Defense World
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):